(2019) 'Dietary nutrients for glutathione support', Nutrients , 11(9), 2073
That is a radically different outcome than the registration trials, and it demonstrates that the lean mass loss is not inevitable
It is the most common side effect by a wide margin, and it typically follows a predictable pattern
The Real-Bari study, launched on June 26, 2026, at the Grupo Hospitalar Conceio in Porto Alegre, Rio Grande do Sul, is enrolling 250 patients with severe obesity over a two-year period to evaluate effectiveness, safety, and cost
This approach is particularly relevant in 2026, as demand for GLP-1 therapies continues to outpace traditional access models